• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Meta-Analysis: Are Oral GnRh Antagonists for Uterine Fibroids Safe and Effective?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Oral gonadotropin-releasing hormone (GnRH) antagonists like elagolix and relugolix have shown promise as a medical treatment option for symptomatic uterine fibroids
  • Niaz et al. (Journal of Obstetrics and Gynaecology Canada, 2022) assess the efficacy and safety of oral GnRH antagonists in women with symptomatic uterine fibroids

METHODS:

  • Systematic review and meta-analysis
  • Study inclusion criteria
    • Clinical trials | Observational studies
    • Studies that provided efficacy and safety data in clinical terms (i.e., reduction in menstrual bleeding and discomfort, changes in the size of leiomyoma and uterine volume, etc.)
  • Study design
    • Risk of bias in RCTs was assessed
  • Primary outcome
    •  Safety and efficacy outcomes as treatment for uterine fibroids

RESULTS:

  • 9 RCTs | 3058 women
    • Risk of bias was generally low among the included trials

Relugolix

  • Mean change in bleeding and pelvic discomfort score change (from baseline)
    • Relugolix + estradiol/norethindrone acetate (E2/NETA): range –45 to –51.7
    • Relugolix + delayed E2/NETA: range –48.9 to –51.3
    • Placebo: range –16.1 to –18.3
  • Mean blood loss reduction
    • Relugolix + E2/NETA: –84.3 mL
    • Relugolix + delayed E2/NETA: range –88.2 to –89.4 mL
    • Placebo: range –15.1 to –23.2 mL

Elagolix

  • Least square mean change in menstrual blood loss
    • Elagolix alone: range –184 to –273 mL
    • Elagolix + E2/NETA: range –168 to –198 mL
    • Elagolix + estrogen/progesterone: 216 mL
    • Placebo: range 0.8 to –79 mL

Adverse effects

  • Most common: Hot flashes | Night sweats | Loss of mineral bone density
  • Overall, treatment well tolerated
  • Add-back therapy were associated with lower incidence and lesser severity of hot flashes

CONCLUSION:

  • Oral GnRH antagonists, both alone and in combination with estradiol/norethindrone acetate, were effective at improving symptoms of uterine fibroids in premenopausal patients
  • The safety of these medications is also well established
  • The authors state

Unlike GnRH agonists, which need to be administered systemically and have an initial flare effect before downregulation, oral GnRH antagonists offer promising results and could become the preferred treatment in the future because of their ease of administration

They can be used in patients refractory to other drugs 

Learn More – Primary Sources:

Efficacy and Safety of Oral GnRh Antagonists in Patients With Uterine Fibroids: A Systematic Review

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Does Elagolix Reduce Heavy Menstrual Bleeding Associated with Uterine Fibroids?
RCT Results: Does Relugolix Combined with Estradiol and Progestin Reduce Fibroid-Associated Heavy Menstrual Bleeding?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site